Anti-Lysophospholipase 1/LPL-I antibody [EPR3667]
- 20ul selling size
- RabMAb
- Recombinant
- KO Validated
- What is this?
5
(1 Review)
|
(21 Publications)
Rabbit Recombinant Monoclonal Lysophospholipase 1/LPL-I antibody. Suitable for WB and reacts with Mouse, Rat, Human samples. Cited in 21 publications.
View Alternative Names
APT1, LPL1, LYPLA1, Acyl-protein thioesterase 1, APT-1, hAPT1, Lysophospholipase 1, Lysophospholipase I, Palmitoyl-protein hydrolase, LPL-I, LysoPLA I
- WB
Lab
Western blot - Anti-Lysophospholipase 1/LPL-I antibody [EPR3667] (AB91606)
Lanes 1- 2 : Merged signal (red and green). Green - ab91606 observed at 25 kDa. Red - Anti-GAPDH antibody [6C5] - Loading Control (ab8245) observed at 37 kDa.
ab91606 was shown to react with Lysophospholipase 1/LPL-I in wild-type HEK-293T cells in western blot. Loss of signal was observed when knockout cell line ab266195 (knockout cell lysate ab257509) was used. Wild-type HEK-293T and LYPLA1 knockout HEK-293T cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab91606 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) overnight at 4°C at a 1 in 5000 dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-Lysophospholipase 1/LPL-I antibody [EPR3667] (ab91606) at 1/5000 dilution
Lane 1:
Wild-type HEK-293T cell lysate at 20 µg
Lane 2:
LYPLA1 knockout HEK-293T cell lysate at 20 µg
Lane 2:
Western blot - Human LYPLA1 (Lysophospholipase 1/LPL-I) knockout HEK-293T cell line (<a href='/en-us/products/cell-lines/human-lypla1-lysophospholipase-1-lpl-i-knockout-hek-293t-cell-line-ab266195'>ab266195</a>)
Predicted band size: 25 kDa
Observed band size: 25 kDa
false
- WB
Lab
Western blot - Anti-Lysophospholipase 1/LPL-I antibody [EPR3667] (AB91606)
Lane 1 : Wild-type HAP1 whole cell lysate (40 μg)
Lane 2 : LYPLA1 knockout HAP1 whole cell lysate (40 μg)
Lanes 1 - 2 : Merged signal (red and green). Green - ab91606 observed at 25 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab91606 was shown to specifically react with LYPLA1 in wild-type HAP1 cells. No band was obsereved when LYPLA1 knockout samples were examined. Wild-type and LYPLA1 knockout samples were subjected to SDS-PAGE. ab91606 and ab8245 (Mouse anti-GAPDH loading control) were incubated overnight at 4°C at 1/5000 dilution and 1/10,000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-Lysophospholipase 1/LPL-I antibody [EPR3667] (ab91606)
Predicted band size: 25 kDa
false
- WB
Unknown
Western blot - Anti-Lysophospholipase 1/LPL-I antibody [EPR3667] (AB91606)
All lanes:
Western blot - Anti-Lysophospholipase 1/LPL-I antibody [EPR3667] (ab91606) at 1/5000 dilution
Lane 1:
Fetal liver tissue lysate at 10 µg
Lane 2:
Fetal heart tissue lysate at 10 µg
Lane 3:
Human spleen tissue lysate at 10 µg
Secondary
All lanes:
HRP labelled goat anti-rabbit IgG at 1/1000 dilution
Predicted band size: 25 kDa
false
- WB
Lab
Western blot - Anti-Lysophospholipase 1/LPL-I antibody [EPR3667] (AB91606)
All lanes:
Western blot - Anti-Lysophospholipase 1/LPL-I antibody [EPR3667] (ab91606) at 1/5000 dilution
Lane 1:
Human liver tissue lysates at 20 µg
Lane 2:
Human fetal heart tissue lysates at 20 µg
Lane 3:
Mouse liver tissue lysates at 20 µg
Lane 4:
Rat liver tissue lysates at 20 µg
Secondary
All lanes:
Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Predicted band size: 25 kDa
Observed band size: 25 kDa
false
- WB
Unknown
Western blot - Anti-Lysophospholipase 1/LPL-I antibody [EPR3667] (AB91606)
All lanes:
Western blot - Anti-Lysophospholipase 1/LPL-I antibody [EPR3667] (ab91606) at 1/5000 dilution
Lane 1:
Mouse heart lysate at 10 µg
Lane 2:
Mouse kidney lysate at 10 µg
Lane 3:
Mouse spleen lysate at 10 µg
Lane 4:
Rat kidney lysate at 10 µg
Secondary
All lanes:
HRP labelled goat anti-rabbit IgG at 1/1000 dilution
Predicted band size: 25 kDa
false
Related conjugates and formulations (1)
-
Anti-Lysophospholipase 1/LPL-I antibody [EPR3667] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Lysophospholipase 1 plays a role in maintaining lipid homeostasis. It does not function as part of a larger protein complex acting independently in the regulation of lipid turnover. By breaking down lysophospholipids the enzyme helps balance the cellular lipid composition ensuring proper membrane integrity and cellular signaling. This regulation is critical in tissues that have high turnover of lipids like the brain and liver.
Pathways
Lysophospholipase 1 participates in lipid metabolism and glycerophospholipid biosynthesis pathways. The enzyme helps process intermediates in these pathways facilitating energy production and phospholipid remodeling. In terms of related proteins LPL-I functions in coordination with phospholipase A2 in lipid degradation and this relationship impacts the synthesis of bioactive lipid mediators.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (21)
Recent publications for all applications. Explore the full list and refine your search
Communications biology 8:477 PubMed40121269
2025
Applications
Unspecified application
Species
Unspecified reactive species
Cell death & disease 15:674 PubMed39277582
2024
Applications
Unspecified application
Species
Unspecified reactive species
Aging 15:9499-9520 PubMed37751585
2023
Applications
Unspecified application
Species
Unspecified reactive species
Regenerative therapy 24:351-360 PubMed37674692
2023
Applications
Unspecified application
Species
Unspecified reactive species
Reproductive sciences (Thousand Oaks, Calif.) 31:128-138 PubMed37603234
2023
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in pharmacology 14:1124633 PubMed37251330
2023
Applications
Unspecified application
Species
Unspecified reactive species
Stem cells translational medicine 12:307-321 PubMed37010483
2023
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 13:2933 PubMed36806358
2023
Applications
Unspecified application
Species
Unspecified reactive species
Cell metabolism 35:332-344.e7 PubMed36634673
2023
Applications
Unspecified application
Species
Unspecified reactive species
iScience 25:104996 PubMed36105595
2022
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com